CN Stock MarketDetailed Quotes
300158 Shanxi Zhendong Pharmaceutical
- 3.56
- -0.38-9.64%
Market Closed Sep 10 15:00 CST
3.58BMarket Cap-127142P/E (TTM)
3.83High3.47Low510.46KlotVolume3.83Open3.94Pre Close183.02MTurnover5.10%Turnover RatioLossP/E (Static)1.01BShares8.4752wk High0.72P/B3.56BFloat Cap3.4752wk Low4.73Limit Up1.00BShs Float12.96Historical High3.15Limit Down9.14%Amplitude0.48Historical Low--Dividend TTM3.59Avg Price252.06KlotAsk--Div YieldTTM100Lot Size243.50KlotBid
Shanxi Zhendong Pharmaceutical Key Stats
All
YOY
| (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | (Q3)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -22.05%1.51B | -17.79%782.13M | -2.75%3.63B | -0.55%2.78B | 12.01%1.93B | 7.04%951.42M | -26.80%3.73B | -30.93%2.8B | -34.80%1.73B | -31.27%888.84M |
| Operating revenue | -22.05%1.51B | -17.79%782.13M | -2.75%3.63B | -0.55%2.78B | 12.01%1.93B | 7.04%951.42M | -26.80%3.73B | -30.93%2.8B | -34.80%1.73B | -31.27%888.84M |
| Other operating revenue | 58.29%13.02M | ---- | -69.73%19.37M | ---- | -73.90%8.23M | ---- | -3.20%63.98M | ---- | -48.36%31.52M | ---- |
| Total operating cost | -20.53%1.53B | -18.68%795.15M | -3.69%3.78B | -2.20%2.8B | 9.27%1.92B | 8.52%977.79M | -21.71%3.92B | -23.75%2.86B | -27.52%1.76B | -23.40%901.04M |
| Operating cost | -22.64%760.36M | -13.77%434.92M | -4.78%1.8B | -1.13%1.37B | 14.83%982.9M | 9.97%504.39M | -8.01%1.89B | -8.40%1.39B | -12.49%855.99M | -7.36%458.67M |
| Operating tax surcharges | -10.78%16.24M | -11.85%8.37M | -2.68%34.83M | 1.50%25.34M | 8.42%18.2M | 29.76%9.49M | -40.77%35.79M | -42.47%24.97M | -44.35%16.79M | -35.44%7.32M |
| Operating expense | -25.00%536.74M | -27.53%265.26M | -2.75%1.48B | -5.07%1.07B | 7.54%715.65M | 11.94%366.02M | -33.15%1.52B | -37.38%1.13B | -42.87%665.48M | -40.46%326.97M |
| Administration expense | -7.51%113.34M | -2.75%48.6M | -1.73%285.88M | 8.54%198.36M | 1.40%122.55M | -6.58%49.97M | -25.72%290.91M | -20.31%182.74M | -24.36%120.86M | -23.36%53.49M |
| Financial expense | 81.99%-1.21M | 53.83%-448.96K | -195.78%-9.57M | -169.98%-7.84M | -172.75%-6.7M | -135.97%-972.39K | -30.43%9.99M | 7.74%11.2M | 35.12%9.21M | -25.15%2.7M |
| -Interest expense (Financial expense) | 61.82%1.52M | -36.40%295.18K | -91.26%1.2M | -92.35%998.65K | -90.13%941.62K | -87.25%464.08K | -29.29%13.73M | -7.10%13.06M | 7.96%9.54M | -7.41%3.64M |
| -Interest Income (Financial expense) | 55.66%-3.51M | 44.34%-1.01M | -85.88%-11.59M | -142.63%-9.98M | -220.58%-7.91M | -71.60%-1.82M | -4.45%-6.24M | 8.03%-4.11M | 7.19%-2.47M | -74.17%-1.06M |
| Research and development | 14.18%101.32M | -21.35%38.45M | 7.25%191.02M | 10.58%137.28M | -1.44%88.74M | -5.79%48.89M | -18.57%178.11M | -16.36%124.15M | 4.36%90.04M | 9.53%51.89M |
| Credit Impairment Loss | 36.00%-14.1M | 64.90%-604.98K | -62.19%17.45M | -3,816.78%-21.64M | -3,237.30%-22.04M | 68.78%-1.72M | 491.18%46.15M | -123.13%-552.38K | -185.70%-660.28K | -3.27%-5.52M |
| Asset Impairment Loss | 14.81%-9.25M | 20,829.54%1.63M | -589.99%-36.24M | -14,904.71%-15.77M | -7,602.47%-10.86M | 105.53%7.79K | 68.99%-5.25M | -75.50%106.52K | 95.38%-140.97K | ---140.97K |
| Adjustment items of total operating cost | ---- | ---- | ---- | ---- | ---- | --0.01 | ---- | ---- | ---- | ---- |
| Other net revenue | 279.38%64.62M | 34.55%45.31M | -35.31%121.43M | -81.64%23.5M | -81.21%17.03M | 11.25%33.67M | -93.82%187.72M | 49.23%128.03M | 61.86%90.66M | 4,876.31%30.27M |
| Fair value change income | 47.38%6.87M | -33.00%2.65M | -83.11%1.96M | 537.08%3.63M | 660.85%4.66M | 1,326.34%3.95M | 1,293.86%11.59M | ---831.57K | ---831.57K | 4,778.01%277.21K |
| Invest income | 70.74%28.91M | 72.64%16.89M | -20.89%43.08M | -59.16%23.74M | -64.90%16.93M | 182.19%9.78M | -98.16%54.46M | 288.40%58.11M | 4,223.31%48.25M | 4,165.83%3.47M |
| Asset deal income | 6,731.70%11.62M | 12,142.74%10.21M | 191.10%291.96K | --192.61K | --170.15K | --83.38K | -67,355.96%-320.48K | ---- | ---- | ---- |
| Other revenue | 44.05%40.56M | -32.61%14.54M | 17.03%94.89M | -53.16%33.35M | -36.07%28.16M | -32.98%21.57M | -27.60%81.09M | 4.69%71.19M | -22.96%44.05M | 447.59%32.18M |
| Operating profit | 55.42%44.42M | 342.07%32.29M | -406.44%-29.98M | -82.95%11.74M | -50.66%28.58M | -59.57%7.3M | -100.19%-5.92M | -82.34%68.84M | -79.05%57.93M | -84.62%18.07M |
| Add:Non operating Income | 5.35%1.74M | -42.14%310.9K | -54.75%1.98M | 42.35%2.07M | 133.92%1.65M | 193.50%537.32K | -13.75%4.38M | -69.03%1.46M | 207.88%704.27K | 97.73%183.08K |
| Less:Non operating expense | 630.05%5.4M | 302.41%1.61M | 159.28%9.69M | -14.59%2.65M | -74.22%739.52K | 101.33%399.44K | -64.48%3.74M | 6.83%3.1M | 38.43%2.87M | -90.69%198.4K |
| Total profit | 38.22%40.76M | 316.46%30.99M | -613.81%-37.69M | -83.39%11.16M | -47.12%29.49M | -58.77%7.44M | -100.17%-5.28M | -82.84%67.19M | -79.69%55.77M | -84.37%18.05M |
| Less:Income tax cost | -26.75%12.66M | 3.62%8.65M | -80.32%10.18M | -66.97%15.29M | -47.38%17.28M | -18.49%8.34M | -89.79%51.72M | -40.00%46.29M | -47.06%32.84M | -49.84%10.24M |
| Net profit | 130.17%28.1M | FLtoP22.35M | FPtoL-47.87M | SL-4.13M | -46.74%12.21M | SL-902.07K | SL-57M | -93.35%20.89M | -89.22%22.92M | -91.78%7.81M |
| Net profit from continuing operation | 130.17%28.1M | 2,577.33%22.35M | 16.02%-47.87M | -119.79%-4.13M | -46.74%12.21M | -111.54%-902.07K | -102.46%-57M | -54.12%20.89M | -89.22%22.92M | -91.78%7.81M |
| Less:Minority Profit | -9.54%-2.56M | -48.70%-754.43K | 31.95%-3.89M | 15.37%-3.26M | -35.53%-2.33M | 62.00%-507.34K | 26.85%-5.71M | 55.37%-3.85M | 78.70%-1.72M | 48.05%-1.34M |
| Net profit of parent company owners | 110.81%30.66M | 5,952.52%23.1M | 14.24%-43.98M | -103.53%-874.2K | -40.99%14.54M | -104.31%-394.73K | -101.96%-51.29M | -92.34%24.74M | -88.83%24.65M | -90.63%9.15M |
| Earning per share | ||||||||||
| Basic earning per share | 109.86%0.0298 | 5,725.00%0.0225 | 14.23%-0.0428 | -103.73%-0.0009 | -40.83%0.0142 | -104.49%-0.0004 | -101.96%-0.0499 | -92.33%0.0241 | -88.83%0.024 | -90.63%0.0089 |
| Diluted earning per share | 109.86%0.0298 | 5,725.00%0.0225 | 14.23%-0.0428 | -103.73%-0.0009 | -40.83%0.0142 | -104.49%-0.0004 | -101.96%-0.0499 | -92.33%0.0241 | -88.83%0.024 | -90.63%0.0089 |
| Other composite income | 101.05%330.13K | -100.04%-4.44 | -42,328.25%-31.31M | -2,432.82%-31.34M | -3,378.35%-31.34M | 1,933.18%10.58K | -82.55%74.15K | 1,008,702.40%1.34M | 437,534.26%955.84K | 101.88%520.59 |
| Other composite income of parent company owners | 101.05%330.13K | -100.04%-4.44 | -42,328.25%-31.31M | -2,432.82%-31.34M | -3,378.35%-31.34M | 1,933.18%10.58K | -82.55%74.15K | 1,008,702.40%1.34M | 437,534.26%955.84K | 101.88%520.59 |
| Total composite income | 248.65%28.43M | 2,606.74%22.35M | -39.10%-79.18M | -259.55%-35.48M | -180.09%-19.13M | -111.41%-891.48K | -102.18%-56.92M | -92.93%22.24M | -88.77%23.88M | -91.78%7.82M |
| Total composite income of parent company owners | 284.52%30.99M | 6,113.77%23.1M | -47.02%-75.3M | -223.49%-32.22M | -165.60%-16.79M | -104.20%-384.14K | -101.96%-51.22M | -91.92%26.09M | -88.40%25.6M | -90.62%9.15M |
| Total composite income of minority owners | -9.54%-2.56M | -48.70%-754.43K | 31.95%-3.89M | 15.37%-3.26M | -35.53%-2.33M | 62.00%-507.34K | 26.85%-5.71M | 55.37%-3.85M | 78.70%-1.72M | 48.05%-1.34M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- |
| Auditor | -- | -- | CITIC Certified Public Accountants (Special General Partnership) | -- | -- | -- | CITIC Certified Public Accountants (Special General Partnership) | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Analysis
Price Target
No Data
Heat List
CN
Overall
Symbol
Latest Price
% Chg